gannet53 a drug strategy targeting stabilised mutant p53 figure … · 2015. 9. 7. · bérard lyon...
TRANSCRIPT
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
PROJECT�PARTNERS�
Medical� University� Innsbruck� •� Katholieke� Universiteit� Leuven� •� Charité� Universitätsmedizin� Berlin� •� Medizinische�
Universität�Wien�•�Universitätsklinikum�Hamburg-Eppendorf�•�Assistance�Publique-Hôpitaux�de�Paris�•Centre�Léon�
Bérard� Lyon� •� AGO� Research� GmbH� •� NOGGO� eV� •� ARCAGY� GINECO� •� Universitätsmedizin� Göttingen� •� xailabs�
GmbH� •� ONCOLAB� Diagnostics� GmbH� •� Kliniken� Essen-Mitte� •� Technische� Universität� Dresden� •� Centre� François�
Baclesse�Caen�•�Ernst-Moritz-Arndt-Universität�Greifswald�•�Otto-von-Guericke-Universität�Magdeburg
This project has received funding from the
European Union’s Seventh Framework Programme for research, technological
development and demonstration under grant agreement no 602602.
GANNET53 A drug strategy targeting stabilised mutant p53
to fight metastatic platinum-resistant ovarian cancer EUROPEAN PROJECT
Sponsor: Medical University of Innsbruck, Austria, Department of Obstetrics and Gynecology
Coordinator: Prof. Dr. Nicole Concin
Figure 1: THE GANNET53 PROJECT PARTNERS
ORGANISATION GROUP LEADER
Medical University Innsbruck, AUSTRIA
Nicole Concin Christian Marth
Katholieke Universiteit Leuven, BELGIUM
Ignace Vergote
Charité - Universitätsmedizin Berlin, GERMANY
Jalid Sehouli Ioana Braicu
University Medical Centre Hamburg-Eppendorf, GERMANY
Sven Mahner
Medical University of Vienna, AUSTRIA
Alexander Reinthaller Dan Cacsire Castillo
Assistance Publique – Hôpitaux de Paris, FRANCE
Hôpital européen Georges-Pompidou Hôpital Tenon
Eric Pujade-Lauraine
Centre Anticancereux Léon Bérard, FRANCE
Isabelle Ray-Coquard
AGO Research GmbH, GERMANY
Sven Mahner
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
PROJECT�PARTNERS�
Medical� University� Innsbruck� •� Katholieke� Universiteit� Leuven� •� Charité� Universitätsmedizin� Berlin� •� Medizinische�
Universität�Wien�•�Universitätsklinikum�Hamburg-Eppendorf�•�Assistance�Publique-Hôpitaux�de�Paris�•Centre�Léon�
Bérard� Lyon� •� AGO� Research� GmbH� •� NOGGO� eV� •� ARCAGY� GINECO� •� Universitätsmedizin� Göttingen� •� xailabs�
GmbH� •� ONCOLAB� Diagnostics� GmbH� •� Kliniken� Essen-Mitte� •� Technische� Universität� Dresden� •� Centre� François�
Baclesse�Caen�•�Ernst-Moritz-Arndt-Universität�Greifswald�•�Otto-von-Guericke-Universität�Magdeburg
This project has received funding from the
European Union’s Seventh Framework Programme for research, technological
development and demonstration under grant agreement no 602602.
Nord-Ostdeutsche Gesellschaft für Gynaek-ologische Onkologie, GERMAN
Jalid Sehouli
ARCAY – GINECO Association de Recherche dans le Cancers dont Gynécologique – Groupe des Investigateurs Nationaux dans l’Etude des Cancers Ovariens, FRANCE
Eric Pujade-Lauraine
University Hospital Goettingen – Georg-August University Goettingen, GERMANY
Ute M. Moll
OncoLab Diagnostics GmbH, AUSTRIA
Robert Zeillinger
xailabs GmbH, GERMANY
Salvatore Vanasco
Kliniken Essen Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH, GERMANY
Philipp Harter
Technical University of Dresden University Hospital Carl Gustav Carus Dresden, GERMANY
Ulrich Canzler
Centre François Baclesse Centre de Lutte Contre le Cancer (CLCC) de Caen, FRANCE
Florence Joly-Lobbedez
University of Greifswald University Clinic Greifswald, GERMANY
Alexander Mustea
University of Magdeburg University Clinic Magdeburg, GERMANY
Atanas Ignatov
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
PROJECT�PARTNERS�
Medical� University� Innsbruck� •� Katholieke� Universiteit� Leuven� •� Charité� Universitätsmedizin� Berlin� •� Medizinische�
Universität�Wien�•�Universitätsklinikum�Hamburg-Eppendorf�•�Assistance�Publique-Hôpitaux�de�Paris�•Centre�Léon�
Bérard� Lyon� •� AGO� Research� GmbH� •� NOGGO� eV� •� ARCAGY� GINECO� •� Universitätsmedizin� Göttingen� •� xailabs�
GmbH� •� ONCOLAB� Diagnostics� GmbH� •� Kliniken� Essen-Mitte� •� Technische� Universität� Dresden� •� Centre� François�
Baclesse�Caen�•�Ernst-Moritz-Arndt-Universität�Greifswald�•�Otto-von-Guericke-Universität�Magdeburg
This project has received funding from the
European Union’s Seventh Framework Programme for research, technological
development and demonstration under grant agreement no 602602.
Figure 2: THE GANNET53 RECRUITMENT STRATEGY
Figure 3: THE GANNET53 PHASE II STUDY DESIGN
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
PROJECT�PARTNERS�
Medical� University� Innsbruck� •� Katholieke� Universiteit� Leuven� •� Charité� Universitätsmedizin� Berlin� •� Medizinische�
Universität�Wien�•�Universitätsklinikum�Hamburg-Eppendorf�•�Assistance�Publique-Hôpitaux�de�Paris�•Centre�Léon�
Bérard� Lyon� •� AGO� Research� GmbH� •� NOGGO� eV� •� ARCAGY� GINECO� •� Universitätsmedizin� Göttingen� •� xailabs�
GmbH� •� ONCOLAB� Diagnostics� GmbH� •� Kliniken� Essen-Mitte� •� Technische� Universität� Dresden� •� Centre� François�
Baclesse�Caen�•�Ernst-Moritz-Arndt-Universität�Greifswald�•�Otto-von-Guericke-Universität�Magdeburg
This project has received funding from the
European Union’s Seventh Framework Programme for research, technological
development and demonstration under grant agreement no 602602.
B
A
Figure 4: Proximity Ligation Assay (PLA) detecting Hsp90-mutp53 interaction applied on: FFPE ovarian cancer tissue (left), and ascites of an ovarian cancer patient (right)
Figure 5: Immunofluorecence staining of circulation tumour cells (CTC) from blood samples. A: Positive control of T47D cells spiked in leucocytes of a healthy donor; B: Example of a CTC detected in blood of an ovarian cancer patient.
LEGAL NOTE: All rights to the images displayed in Figures 4 and 5 are reserved by the GANNET53 consortium